About Us

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support pharmaceutical and biotech partners in the development of better therapies. Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. 

The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people 'extra time'. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.​ 

Oncimmune is headquartered at its laboratory facility in Nottingham, UK, and has a discovery research centre in Dortmund, Germany.

Useful Information

Submission to Health and Social Care Committee inquiry

View document

Research paper - lung cancer survival and predictions

View document

Find us at an Event

Bio-Europe Spring
22 Mar - 25 Mar 2021


D6 Thane Road
NG90 6BH
United Kingdom


Visit website


Let’s connect